Compare Adaptive Biotechnologies Corp (ADPT) vs Advanced Micro Devices (AMD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Advanced Micro Devices — how do they compare? Adaptive Biotechnologies Corp trades at $20.01 (market cap $3.33B), while Advanced Micro Devices trades at $510.36 (market cap $841.57B). The key difference: Advanced Micro Devices is far larger — about 252.7× Adaptive Biotechnologies Corp's market cap. Which is the better fit depends on your goals.
| ADPT | AMD | |
|---|---|---|
Market Cap | $3.33B | $841.57B |
Sector | Health | Technology |
52-Week High | $22.37 | $580.91 |
52-Week Low | $10.24 | $137.82 |
Enterprise Value | $3.19B | $833.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
AMD trades at $552.05, up 6.61% today and near its 52-week high, with strong technical momentum and bullish moving averages. The company reported robust Q1 2026 earnings of $1.37 EPS, beating expectations, and shows accelerating revenue growth to $34.64 billion in 2025 with net income surging to $4.34 billion. Analyst sentiment remains overwhelmingly positive with 71% buy ratings.
AMD's AI-driven growth trajectory presents significant upside potential, though premium valuations (P/E 184) and intense semiconductor competition pose risks. The stock's technical strength and fundamental momentum support continued bullish sentiment, but investors should monitor execution against high expectations and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Advanced Micro Devices
Advanced Micro Devices, Inc. (AMD) produces semiconductor products and devices. The Company offers products such as microprocessors, embedded microprocessors, chipsets, graphics, video and multimedia products and supplies it to third-party foundries, as well as provides assembling, testing, and packaging services. AMD serves customers worldwide.
Read more on AMD →
